Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	23899
Country	United States

Received	2015-12-23 08:37
Peer-Review Started	2015-12-24 08:02
To Make the First Decision	2016-01-18 11:51
Return for Revision	2016-01-21 17:35
Revised	2016-01-27 05:24
Second Decision	2016-03-07 15:24
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2016-03-16 15:58
Articles in Press	2016-03-16 15:58
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-04-25 11:31
Publish the Manuscript Online	2016-05-10 08:16

ISSN	1948-5204 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Multitarget stool DNA for colorectal cancer screening: A review and commentary on the United States Preventive Services Draft Guidelines
Manuscript Source	Invited Manuscript
All Author List	Barry M Berger, Bernard Levin and Robert J Hilsden
Funding Agency and Grant Number
Corresponding Author	Barry M Berger, MD, Chief Medical Officer, Medical Affairs, Exact Sciences Corporation, 5801 Research Park Blvd, Madison, WI 53719, United States. bberger@exactsciences.com
Key Words	Colorectal cancer screening; Multitarget stool DNA; Stool DNA; The United States Preventive Services Task Force; Cancer Intervention Surveillance Modeling Network; Fecal immunological technique; Modeling; Interval
Core Tip	Multi-target stool DNA (mt-sDNA) testing was approved for average risk colorectal cancer (CRC) screening by the United States Food and Drug Admini-stration (2014). The evidence supporting mt-sDNA for routine screening use is robust. The clinical efficacy of mt-sDNA every three years, measured by life-years gained, and CRC deaths averted, is similar to that of other screening strategies more specifically recommended by the United States Preventive Services Task Force. In an irregularly screened population, however, tests with the highest point sensitivity and reasonable specificity like mt-sDNA are more likely to reduce CRC related morbidity and mortality than less sensitive tests that depend on annual adherence to achieve high programmatic sensitivity.
Publish Date	2016-05-10 08:16
Citation	Berger BM, Levin B, Hilsden RJ. Multitarget stool DNA for colorectal cancer screening: A review and commentary on the United States Preventive Services Draft Guidelines. World J Gastrointest Oncol 2016; 8(5): 450-458
URL	http://www.wjgnet.com/1948-5204/full/v8/i5/450.htm
DOI	http://dx.doi.org/10.4251/wjgo.v8.i5.450

Full Article (PDF)	WJGO-8-450.pdf
Full Article (Word)	WJGO-8-450.doc
Manuscript File	23899-Review.docx
Answering Reviewers	23899-Answering reviewers.pdf
Audio Core Tip	23899-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	23899-Conflict-of-interest statement.pdf
Copyright License Agreement	23899-Copyright assignment.pdf
Peer-review Report	23899-Peer-review(s).pdf
Scientific Misconduct Check	23899-Scientific misconduct check.pdf
Scientific Editor Work List	23899-Scientific editor work list.pdf